Date: 05th August, 2026

To,
BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730

Subject: Outcome of the Board Meeting

Dear Sir / Madam,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, August 05, 2026 has inter-alia, considered, adopted and approved following items of business:

1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2026 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditor of the Company; copies of which are attached hereunder;

   In furtherance to the intimation filed by the Company dated July 30, 2026; the trading window for trading in securities of the Company by insiders closed on July 01, 2026 till the end of 48 hours after the declaration of outcome of this Board Meeting.

The Board Meeting commenced at 10:30 a.m. and concluded at 11:20 a.m.

Kindly oblige and take the same on your Records.

Thanking you,

FOR FREDUN PHARMACEUTICALS LIMITED

FREDUN NARIMAN MEDHORA
Digitally signed by FREDUN NARIMAN MEDHORA
Date: 2026.08.05 11:29:35 +05'30'

FREDUN MEDHORA
MANAGING DIRECTOR
DIN: 01745348

R.H.Nisar & Co.
Chartered Accountant
A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Company') for the quarter ended 30th June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors on 05th August, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724

5. The Statement regarding the Standalone figures for the quarter ended 31 March 2026, as reported in the statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026, and published year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us and not subject to audit.

   Our conclusion on the statement is not modified in respect of the above matter.

FOR R H NISAR & CO.
CHARTERED ACCOUNTANTS
FIRM'S REGISTRATION NUMBER: 120895W

RAKESH NISAR
PROPRIETOR
MEMBERSHIP NO. 103659
UDIN: 26103659NCTUDR3483

PLACE: MUMBAI
DATE: 05.08.2026

R.H. NISAR & CO. CHARTERED ACCOUNTANTS MEM. NO. 103659

R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Parent's Board of Directors on 05th August, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The statement includes the results of the following entities:

   Incorporated in India

   a. Fredun Retail Private Limited
   b. One Pet Stop Private Limited
   c. Wagr Retail Private Limited

R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement regarding the Consolidated figures for the quarter ended 31 March 2026, as reported in the statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026, and published year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us and not subject to audit.

   Our conclusion on the statement is not modified in respect of the above matter.

FOR R H NISAR & CO.
CHARTERED ACCOUNTANTS
FIRM'S REGISTRATION NUMBER: 120895W

RAKESH NISAR
PROPRIETOR
MEMBERSHIP NO. 103659
UDIN: 26103659QAZPPO5933

PLACE: MUMBAI
DATE: 05.08.2026

R. H. NISAR & CO.
CHARTERED ACCOUNTANTS
MEM. NO.
103659

FREDUN PHARMACEUTICALS LIMITED

Regd. Office : Urmi Estate , 11th Floor , Ganpatrao Kadam Marg , Lower Parel (W) , Mumbai -400 013

CIN NO. : L24239MH1987PLC043662

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

Rs. In Lakhs

		Standalone				Consolidated			
		Quarter Ended			Year Ended	Quarter Ended			Year Ended
		UnAudited	Audited	UnAudited	Audited	UnAudited	Audited	UnAudited	Audited
	PARTICULARS	30.06.26	31.03.26	30.06.25	31.03.26	30.06.26	31.03.26	30.06.25	31.03.26
1	**Income from Operations**								
	Net Sales /IncomeFrom Operation (Net of GST)	22,775.55	21,041.20	11,940.29	63,332.65	22,775.55	21,041.20	11,940.29	63,332.65
2	Other Operating Income	49.24	264.00	45.21	579.52	49.24	264.31	45.21	579.84
3	Total income from operatoins (net)	**22,824.79**	**21,305.20**	**11,985.50**	**63,912.17**	**22,824.79**	**21,305.51**	**11,985.50**	**63,912.49**
4	**Expenses**								
	a) Cost of Material Consumed	17,846.48	17,354.16	9,032.62	48,075.96	17,846.48	17,354.15	9,032.62	48,075.96
	b) Cost of Material Consumed for R & D	126.14	186.34	75.47	507.77	126.14	186.33	75.47	507.77
	c) Other R & D Expenses	-	-	-	-	-	-	-	-
	d) Changes in inventories of finished goods, work-in-progress and stock in trade	(635.05)	(2,209.03)	(666.14)	(3,169.31)	(635.05)	(2,209.02)	(666.14)	(3,169.31)
	e) Manufacturing & Service Cost	407.35	464.66	363.91	1,566.91	407.35	464.66	363.91	1,566.91
	f) Finance Costs	861.81	1,448.51	653.17	3,929.76	861.81	1,448.51	653.17	3,929.76
	g) Employess benefits expenses	712.08	886.45	763.39	3,294.34	712.08	886.45	763.39	3,294.34
	h) Depreciation and amortisation expenses	357.09	311.27	141.91	791.38	357.09	315.05	141.91	824.67
	i) Other Expenses	1,090.12	1,709.52	717.13	4,157.16	1,093.70	1,734.57	717.13	4,182.77
	Total expenses	**20,766.02**	**20,151.88**	**11,081.46**	**59,153.97**	**20,769.60**	**20,180.70**	**11,081.46**	**59,212.89**
5	Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	2,058.77	1,153.32	904.04	4,758.20	2,055.19	1,124.81	904.04	4,699.60
6	Exceptional items / Prior Period Item	-	-	-	-	-	-	-	-
7	Profit/(Loss) from ordinary activities before tax (5-6)	2,058.77	1,153.32	904.04	4,758.20	2,055.19	1,124.81	904.04	4,699.60
8	Tax Expenses	741.96	46.81	227.46	1,437.51	741.96	46.81	227.46	1,437.51
9	Profit/(Loss) from continuing operations	1,316.81	1,106.51	676.58	3,320.69	1,313.23	1,078.00	676.58	3,262.09
10	Profit/(Loss) from discontinued operations	-	-	-	-	-	-	-	-
11	Tax Expense of discontinued operations	-	-	-	-	-	-	-	-
12	Profit/(Loss) from discontinued operations after tax	-	-	-	-	-	-	-	-
13	Profit/ (Loss) for the period	**1,316.81**	**1,106.51**	**676.58**	**3,320.69**	**1,313.23**	**1,078.00**	**676.58**	**3,262.09**
14	Other comprehensive Income								
	A (i) Items that will not be re-classified to profit/ loss	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be re-classified to profit/ loss	-	-	-	-	-	-	-	-
	B (i) Re measurement of post - employment benefit obligations	-	16.55	-	16.55	-	16.55	-	16.95
	C (i) Items that will be re-classified to profit / loss	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will be re-classified to profit/ loss	-	-	-	-	-	-	-	-
	Total Comprehensive Income for the year	**1,316.81**	**1,123.06**	**676.58**	**3,337.24**	**1,313.23**	**1,094.55**	**676.58**	**3,279.00**

FREDUN PHARMACEUTICALS LIMITED

Regd. Office : Urmi Estate , 11th Floor , Ganpatrao Kadam Marg , Lower Parel (W) , Mumbai -400 013

CIN NO. : L24239MH1987PLC043662

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

		Quarter Ended			Year Ended	Quarter Ended			Year Ended
		UnAudited	Audited	UnAudited	Audited	UnAudited	Audited	UnAudited	Audited
	PARTICULARS	30.06.26	31.03.26	30.06.25	31.03.26	30.06.26	31.03.26	30.06.25	31.03.26
15	Paid up Equity Share Capital (Face Value of Rs-10/- each)	551.27	547.27	472.17	547.27	551.27	547.27	472.17	547.27
16	Reserves excluding Revaluation Reserves	-	-	-	-	-	-	-	-
17	Earning per Share (EPS) (before & after extra ordinary items)								
	- Basic Earning Per Share (Rs.)	23.89	20.22	14.33	68.01	23.82	19.70	14.33	66.81
	- Diluted Earning Per Share (Rs.)	22.25	18.70	-	62.33	22.19	18.22	-	61.23
A	1) Public Shareholding								
	Number of shares	30,55,637	30,55,637.00	24,11,277.00	30,55,637.00	30,55,637.00	30,55,637.00	24,11,277	30,55,637
	Percentage of shareholding	**55.43%**	**55.83%**	**51.07%**	**55.83%**	**55.43%**	**55.83%**	**51.07%**	**55.83%**
	2) Promoters and promotor group shareholding								
	a) Pledged/Encumbured								
	- Number of shares	-	-	-	-	-	-	-	-
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-	-	-	-	-
	- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-	-	-	-
	b) Non-encumbered								
	- Number of shares	24,57,053.00	24,17,053.00	23,10,385.00	24,17,053.00	24,57,053.00	24,17,053.00	23,10,385.00	24,17,053.00
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	**44.57%**	**44.17%**	**48.93%**	**44.17%**	**44.57%**	**44.17%**	**48.93%**	**44.17%**
	- Percentage of shares (as a % of total share capital of the Company)	**100.00%**	**100.00%**	**100.00%**	**100.00%**	**100.00%**	**100.00%**	**100.00%**	**100.00%**

Notes

1. The above unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 5, 2026. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

2. The above unaudited financial results for the quarter ended June 30, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Rakesh Nisar & Co have issued limited review reports with unmodified conclusion on the standalone and consolidated unaudited financial results.

3. As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.

4. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the previous financial year.

5. The figures for the earlier periods have been regrouped/ reclassified wherever necessary to make them comparable with those of the current period.

6. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on 5th August 2026 and were approved and taken on record at the meeting of the Board of Directors of the company held on that date

PLACE: MUMBAI

DATE : 05th August 2026

FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR & CFO
FREDUN N. MEDHORA
DIN : 01745348

FREDUN PHARMACEUTICALS LTD. MUMBAI